Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)

Overview

Journal Liver Cancer

Date 2016 Jan 7

PMID 26734577

Citations 6

Authors

Bang-Bin Chen

Takamichi Murakami

Tiffany Ting-Fang Shih

Michiie Sakamoto

Osamu Matsui

Byung-Ihn Choi

Myeong-Jin Kim

Jeong Min Lee

Ren-Jie Yang

Meng-Su Zeng

Ran-Chou Chen

Ja-Der Liang

Affiliations

Soon will be listed here.

Abstract

Current novel imaging techniques in the diagnosis of hepatocellular carcinoma (HCC), with the latest evidence in this field, was discussed at the Asia-Pacific Primary Liver Cancer Expert (APPLE) meeting held in Taipei, Taiwan, in July 2014. Based on their expertise in a specific area of research, the novel imaging group comprised 12 participants from Japan, South Korea, Taiwan, and China and it included 10 abdominal radiologists, one hepatologist, and one pathologist. The expert participants discussed topics related to HCC imaging that were divided into four categories: (i) detection method, (ii) diagnostic method, (iii) evaluation method, and (iv) functional method. Consensus was reached on 10 statements; specific comments on each statement were provided to explain the rationale for the voting results and to suggest future research directions.

Citing Articles

Hepatocellular Carcinoma in Asia: Physician and Patient Perspectives on Surveillance, Diagnosis, and Treatment.

Mohamed R, Wang W, Tanwandee T, Hasan I, Pham C, Lim Y J Gastrointest Cancer. 2024; 55(3):1333-1344.

PMID: 38995318 PMC: 11347480. DOI: 10.1007/s12029-024-01089-5.

Superselective Transarterial Chemoembolization for Unresectable or "Ablation Unsuitable" Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study.

Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L Front Oncol. 2021; 11:678847.

PMID: 34778023 PMC: 8581471. DOI: 10.3389/fonc.2021.678847.

Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations.

Chen Q, Li W, Yu S, Chou Y, Rhim H, Yang X Front Oncol. 2021; 11:621834.

PMID: 34277397 PMC: 8284077. DOI: 10.3389/fonc.2021.621834.

Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).

Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M Liver Cancer. 2018; 7(3):235-260.

PMID: 30319983 PMC: 6167671. DOI: 10.1159/000488035.

MR visible localization device for radiographic-pathologic correlation of surgical specimens.

Kinner S, Schubert T, Nocerino E, Hynes S, Colgan T, Loeffler A Magn Reson Imaging. 2016; 37:159-163.

PMID: 27899330 PMC: 5538025. DOI: 10.1016/j.mri.2016.11.021.

References

Minami Y, Kudo M . Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. World J Gastroenterol. 2011; 17(45):4952-9. PMC: 3236587. DOI: 10.3748/wjg.v17.i45.4952. View

Chen B, Hsu C, Yu C, Kao J, Lee H, Liang P . Hepatic necro-inflammation and elevated liver enzymes: evaluation with MRI perfusion imaging with gadoxetic acid in chronic hepatitis patients. Clin Radiol. 2014; 69(5):473-80. DOI: 10.1016/j.crad.2013.12.003. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y . JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2015; 3(3-4):458-68. PMC: 4531423. DOI: 10.1159/000343875. View

Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N . Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations. Radiology. 2011; 259(1):142-50. DOI: 10.1148/radiol.10100621. View

Takizawa K, Numata K, Morimoto M, Kondo M, Nozaki A, Moriya S . Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol. 2013; 82(9):1471-80. DOI: 10.1016/j.ejrad.2013.04.045. View

Chen B, Hsu C, Yu C, Wei S, Kao J, Lee H . Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol. 2011; 22(1):171-80. DOI: 10.1007/s00330-011-2249-5. View

Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso J . Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2007; 47(1):97-104. DOI: 10.1002/hep.21966. View

Imura S, Shimada M, Utsunomiya T . Recent advances in estimating hepatic functional reserve in patients with chronic liver damage. Hepatol Res. 2014; 45(1):10-9. DOI: 10.1111/hepr.12325. View

10.

Wibmer A, Prusa A, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A . Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. Radiology. 2013; 269(3):777-86. DOI: 10.1148/radiol.13130210. View

11.

Ichikawa S, Ichikawa T, Motosugi U, Sano K, Morisaka H, Enomoto N . Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma. J Magn Reson Imaging. 2013; 39(2):293-7. DOI: 10.1002/jmri.24164. View

12.

Yamamoto A, Ito K, Tamada T, Higaki A, Kanki A, Sato T . Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI. AJR Am J Roentgenol. 2013; 200(6):1254-60. DOI: 10.2214/AJR.12.9136. View

13.

Deng J, Miller F, Rhee T, Sato K, Mulcahy M, Kulik L . Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol. 2006; 17(7):1195-200. DOI: 10.1097/01.RVI.0000227234.81718.EB. View

14.

Strobel D, Bernatik T, Blank W, Schuler A, Greis C, Dietrich C . Diagnostic accuracy of CEUS in the differential diagnosis of small (≤ 20 mm) and subcentimetric (≤ 10 mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial. Ultraschall Med. 2011; 32(6):593-7. DOI: 10.1055/s-0031-1271114. View

15.

Kamel I, Liapi E, Reyes D, Zahurak M, Bluemke D, Geschwind J . Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009; 250(2):466-73. PMC: 6944072. DOI: 10.1148/radiol.2502072222. View

16.

Murakami T, Kim T, Gotoh M, Hasuike Y, Kato N, Miyazawa T . Experimental hepatic dysfunction: evaluation by MR imaging with Gd-EOB-DTPA. Acad Radiol. 1998; 5 Suppl 1:S80-2. DOI: 10.1016/s1076-6332(98)80067-6. View

17.

Kim K, Park M, Ji H, Park J, Han K, Kim M . Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. J Magn Reson Imaging. 2013; 39(2):286-92. DOI: 10.1002/jmri.24161. View

18.

Okada M, Murakami T, Yada N, Numata K, Onoda M, Hyodo T . Comparison between T1 relaxation time of Gd-EOB-DTPA-enhanced MRI and liver stiffness measurement of ultrasound elastography in the evaluation of cirrhotic liver. J Magn Reson Imaging. 2013; 41(2):329-38. DOI: 10.1002/jmri.24529. View

19.

Ooka Y, Kanai F, Okabe S, Ueda T, Shimofusa R, Ogasawara S . Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging. 2012; 31(5):748-54. DOI: 10.1016/j.mri.2012.10.028. View

20.

Bonekamp S, Halappa V, Geschwind J, Li Z, Corona-Villalobos C, Reyes D . Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013; 268(2):431-9. DOI: 10.1148/radiol.13121637. View